id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
DEA-2020-0003-0012,DEA,DEA-2020-0003,Lasmiditan HHS ltr and 8 Factor Analysis 10-23-2019,Supporting & Related Material,,2021-05-25T04:00:00Z,2021,5,,,2021-05-25T16:24:36Z,,0,0,0900006484b34b97
DEA-2020-0003-0011,DEA,DEA-2020-0003,8F Lasmiditan 08062020,Supporting & Related Material,,2021-05-25T04:00:00Z,2021,5,,,2021-05-25T16:16:24Z,,0,0,0900006484b34b5d
DEA-2020-0003-0010,DEA,DEA-2020-0003,Schedules of Controlled Substances: Placement of Lasmiditan in Schedule V,Rule,,2021-05-24T04:00:00Z,2021,5,2021-05-24T04:00:00Z,,2021-05-25T15:49:44Z,2021-10827,0,0,0900006484b2e413
DEA-2020-0003-0007,DEA,DEA-2020-0003,Lasmiditan HHS ltr and 8 Factor Analysis,Supporting & Related Material,,2020-08-17T04:00:00Z,2020,8,,,2020-08-17T14:35:42Z,,0,0,0900006484807b97
DEA-2020-0003-0008,DEA,DEA-2020-0003,8F Lasmiditan 06102020,Supporting & Related Material,,2020-08-17T00:00:00Z,2020,8,,,2020-08-27T14:18:38Z,,0,1,0900006484807b98
DEA-2020-0003-0001,DEA,DEA-2020-0003,Schedules of Controlled Substances: Placement of Lasmiditan in Schedule V,Rule,,2020-01-31T05:00:00Z,2020,1,2020-01-31T05:00:00Z,2020-03-03T04:59:59Z,2021-05-25T15:40:37Z,2020-01957,0,0,0900006484316555
DEA-2020-0003-0009,DEA,DEA-2020-0003,DEA 8-factor review Lasmiditan 01232020 pdf,Supporting & Related Material,,2020-01-31T05:00:00Z,2020,1,,,2020-08-24T18:47:31Z,,0,0,09000064843178f0